Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCX 4251 for Acute Exacerbations of Blepharitis
NCT04675242Phase 2Completed
- Sponsor
- Nicox S.A.
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in blepharitis comparing NCX 4251 with Placebo (2 arms). Primary endpoint: Percentage of Study Eyes With Complete Cure (Score 0) of Blepharitis Signs and Symptoms at Day 15. Started Dec 2020; status: completed.
02
Drugs
NCX 4251
03
Conditions
blepharitis
Beyond the preview
Go deeper on NCT04675242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675242.